Table 5.

Comparisons of prostate tissue immunohistochemistry results between treatment groups.

	All					Cancer					Noncancer
Tissue Biomarkers	Number of subjects with available information	BSE Mean (SE)	Placebo Mean (SE)	P comparing groups	FDR P value	Number of subjects with available information	BSE Mean (SE)	Placebo Mean (SE)	P comparing groups	FDR P value	Number of subjects with available information	BSE Mean (SE)	Placebo Mean (SE)	P comparing groups	FDR P value
H3K18ac H-score	43/39 (Total = 82)	185.8 (9.1)	189.7 (8.0)	0.83	0.91	17/13 (Total = 30)	188.2 (14.6)	184.6 (15.4)	0.90	0.90	26/26 (Total = 52)	184.2 (11.9)	192.3 (9.5)	0.71	0.89
HDAC3 H-score	44/43 (Total = 87)	180.0 (15.0)	172.3 (13.7)	0.64	0.91	17/13 (Total = 30)	167.6 (21.4)	160.0 (24.5)	0.75	0.90	27/30 (Total = 57)	187.5 (20.5)	177.7 (16.7)	0.58	0.89
HDAC6 H-score	44/44 (Total = 88)	187.0 (13.0)	183.0 (12.5)	0.91	0.91	17/14 (Total = 31)	216.5 (20.1)	182.1 (22.0)	0.28	0.70	27/30 (Total = 57)	168.5 (16.3)	183.3 (15.4)	0.43	0.89
Ki67 % positivity	41/42 (Total = 83)	1.8 (0.2)	1.9 (0.3)	0.47	0.91	16/12 (Total = 28)	1.7 (0.4)	1.8 (0.5)	0.84	0.90	25/30 (Total = 55)	1.8 (0.3)	1.9 (0.4)	0.51	0.89
P21 % positivity	43/42 (Total = 85)	2.4 (0.5)	3.1 (0.6)	0.41	0.91	17/13 (Total = 30)	2.0 (0.8)	3.8 (1.2)	0.28	0.70	26/29 (Total = 55)	2.7 (0.7)	2.7 (0.6)	0.94	0.94

Note: P values were calculated using Mann–Whitney U-test due to non-normal distribution.